Estrogen regulation of apoptosis in osteoblasts

Physiology and Behavior

Volumn 99, Issue 2, 2010, Pages 181-185

  Bradford, Peter G ^a   Gerace, Ken V ^a   Roland, Renée L ^a   Chrzan, Brian G ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Apoptosis; Caspase 3 7; Estrogen receptor; Inositol trisphosphate receptor; Osteoporosis

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE RECRUITMENT DOMAIN PROTEIN 5; ESTROGEN; ETOPOSIDE; GENE PRODUCT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PROTEIN BID; PROTEIN BIRC5; PROTEIN ITPR1; PROTEIN LTBR; PROTEIN RIP2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 12; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; TRANSCRIPTION REPRESSION;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MICROARRAY ANALYSIS; OSTEOBLASTS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72649098225     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2009.04.025     Document Type: Article

References (27)

1. Torgerson D.J., and Bell-Syer S.E.M. Hormone replacement therapy and the prevention of nonvertebral fractures: a meta-analysis of randomized trials. J Am Med Assoc 285 22 (2001) 2891-2897
2. Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 288 3 (2002) 321-333
3. Ott S.M. Editorial: long-term safety of bisphosphonates. J Clin Endocrinol Metab 90 3 (2005) 1897-1899
4. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
5. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral and Maxillofac Surg 62 (2004) 527-534
6. Rossouw J.E., Prentice R.L., Manson J.E., Wu L.L., Barad D., Barnabei V.M., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 297 13 (2007) 1465-1477
7. Writing Group for the P.E.P.I. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc 276 (1996) 1389-1396
8. Speroff L., Rowan J., Symons J., Genant H., Wilborn W., et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized control trial. J Am Med Assoc 276 (1996) 1397-1403
9. Bagger Y.Z., Tanko L.B., Alexandersen P., Hansen H.B., Mollgaard A., Ravn P., et al. Two to three years of hormone replacement therapy in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34 (2004) 728-735
10. Middleton E.T., and Steel S.A. The effects of short-term hormone replacement therapy on long-term bone mineral density. Climacteric 10 (2007) 257-263
11. Martin R.B. Targeted bone remodeling involves BMU steering as well as activation. Bone 40 (2007) 1574-1580
12. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 2 (2000) 115-137
13. Xing L., and Boyce B.F. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 328 3 (2005) 709-720
14. Hay E., Lemonnier J., Fromique O., and Marie P.J. Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase c-dependent signaling pathway. J Biol Chem 276 (2001) 29028-29036
15. DeJong R.S., Mulder N.H., Dijksterhhuis D., and DeVries E. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res 15 (1995) 2319-2330
16. Boyce B.F., Li P., Yao Z., Zhang Q., Badell I.R., Schwarz E.M., et al. TNF-alpha and pathologic bone resorption. Keio J Med 54 3 (2005) 127-131
17. Debatin K.M., and Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 23 (2004) 2950-2966
18. Walsh J.G., Cullen S.P., Sheridan C., et al. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci U S A 105 35 (2008) 12815-12819
19. White C, Li C, Yang J, et al. The endoplasmic reticulum gateway to apoptosis by Bcl-XL modulation of the InsP3R. Nature Cell Biol 7:1021-1027.
20. Li C., Wang X., Vais H., Thompson C.B., Foskett J.K., and White C. Apoptosis regulation by Bcl-XL modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating. Proc Natl Acad Sci U S A 104 30 (2007) 12565-12570
21. Orrenius S., Zhivotovsky B., and Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev 4 (2003) 552-565
22. Boehning D., Paterson R.L., and Snyder S.H. Apoptosis and calcium: new roles for cytochrome c and inositol 1,4,5-trisphosphate. Cell Cycle 3 (2004) 252-254
23. Mattson M.P., and Chan S.L. Calcium orchestrates apoptosis. Nat Cell Biol 5 (2003) 1041-1043
24. Bradford P.G., Maglich J.M., and Kirkwood K.L. IL-1β increases type 1 inositol trisphosphate receptor expression and IL-6 secretory capacity in osteoblastic cell cultures. Molec Cell Biol Res Commun 3 (2000) 73-75
25. Jayarman T., and Marks A.R. T cells deficient in inositol 1,4,5-trisphosphate are resistant to apoptosis. Molec Cell Biol 17 (1997) 3005-3012
26. 2+ signals into mitochondria. J Biol Chem 280 (2005) 40892-40900
27. Kirkwood K.L., Homick K., Dragon M.B., and Bradford P.G. Cloning and characterization of the type I inositol 1,4,5-trisphosphate receptor gene promoter. J Biol Chem 272 (1997) 22425-22431